Description
Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions presents cutting edge research on the adverse cardiac effects of both radiotherapy and chemotherapy, brought together by leaders in the field. Cancer treatment-related cardiotoxicity is the leading cause of treatment-associated mortality in cancer survivors and is one of the most common post-treatment issues among survivors of adult cancer. Early detection of the patients prone to developing cardiotoxicity, taking in to account the type of treatment, history and other risk factors, is essential in the fight to decrease cardiotoxic mortality.This illustrated reference describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment. In addition, new guidelines on imaging for the screening and monitoring of these patients are also presented. Anticancer Treatments and Cardiotoxicity is an essential reference for those involved in the research and treatment of cardiovascular toxicity.- Provides algorithms essential for the use of imaging, and biomarkers for the screening and monitoring of patients- Written by world-leading experts in the field of cardiotoxicity- Includes high-quality images, case studies, and test questions- Describes the most effective diagnostic and imaging tools to evaluate and predict the development of cardiac dysfunction for those patients undergoing cancer treatment
Table of Contents
Section I: General Considerations1. Epidemiology and Trend of Prognosis in Cancer Patients2. Categories of Anticancer Treatments3. Classification by Mechanisms of Cardiotoxicity4. Cardiotoxicity of Oncologic Treatments: Is There a Uniform Definition?5. The Impact of RadiotherapySection II: Detrimental Effects of Anticancer Drugs and Radiotherapy on the Heart6. Lessons From Preclinical Models7. Genetic and Epigenetic Risk Factors8. Changes of Myocardial Structure and Function9. Alteration of Heart Valves10. Pericardial Damage11. Effects of Radiotherapy on Vessels and Coronary Arteries12. Cardiac Conduction DisturbancesSection III: Cardiovascular Complications of Cancer Treatments13. Cardiac Rhythm Disturbances14. Acute and Chronic Heart Failure15. Coronary Artery Disease16. Pericardial Effusion and Pericarditis17. Radiation-Induced Carotid Atherosclerosis18. Valvular Heart Disease19. Atrial Fibrillation and Stroke in Cancer PatientsSection IV: Imaging Evaluation of Cardiac Structure and Function in Cancer Patients20. The Role of Echocardiography21. The Role of Cardiovascular Magnetic Resonance (CMR)22. Nuclear Medicine Imaging and CardiotoxicitySection V: Detection of Cardiac Dysfunction and Predictors of Cardiotoxicity23. Detection by Cardiac Imaging: LV Ejection Fraction, Diastolic Dysfunction, Tissue Doppler, and Speckle Tracking Echocardiography24. The Role of Biomarkers: Troponins, BNP, MPO, and Other Biomarkers25. Screening and Comprehensive Follow-Up Evaluation26. Preoperative Assessment for Noncardiac SurgerySection VI: Cardiotoxicity in Childhood27. Cardiotoxicity of Childhood Cancer TreatmentsSection VII: Management of Anticancer Drugs Related Cardiotoxicity28. Nonpharmacologic Therapy29. Beta-Blockers30. Angiotensin-Converting Enzyme Inhibition31. Diuretics32. Antiarrhythmic Drugs33. Anticoagulation in Cancer Patients34. New Drugs: The Beneficial Effects of Ranolazine35. Percutaneous Coronary Intervention and Cardiac Surgery in Cancer Patients36. Focus on the Patient With Known Cardiac Disease37. Multidisciplinary Approach to Cardiac Disease in Cancer PatientsSection VIII: Future Research Priorities38. Pharmacogenomics Screening39. Cardiac Monitoring During Clinical Trials40. Preventive Therapy41. Cardiotoxicity: Future Research Directions
